PPCB
Propanc Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · AU
$1.80
+5.26%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 625.5K | 625.5K | 223.7K | 248.1K | 247.9K |
| SG&A Expense | 17.6M | 17.6M | 57.1M | 1.3M | 1.5M |
| General & Admin Expense | 17.6M | 17.6M | 57.1M | 1.3M | 1.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | 28.8K |
| Total Operating Expenses | 18.2M | 18.2M | 57.3M | 1.5M | 1.8M |
| Cost and Expenses | 18.2M | 18.2M | 57.3M | 1.5M | 1.8M |
| Operating Income (EBIT) | (18.2M) | (18.2M) | (57.3M) | (1.5M) | (1.8M) |
| Non-Operating | |||||
| Interest Income | 161.00 | 161.00 | 9.00 | 60.00 | 36.00 |
| Interest Expense | 430.5K | 430.5K | 563.8K | 665.8K | 532.8K |
| Net Interest Income | (430.4K) | (430.4K) | (563.7K) | (665.8K) | (532.8K) |
| Other Non-Op Income/Expense | (677.1K) | (677.1K) | (1.6M) | (413.6K) | (1.0M) |
| Non-Operating Income (excl Interest) | 246.6K | 246.6K | 1.1M | (252.2K) | 480.9K |
| EBT (Pre-Tax Income) | (18.9M) | (18.9M) | (58.9M) | (1.9M) | (2.8M) |
| Income Tax Expense | — | — | — | (129.1K) | (129.8K) |
| Bottom Line | |||||
| Net Income | (18.9M) | (18.9M) | (58.9M) | (1.8M) | (2.7M) |
| Earnings from Cont. Ops | (18.9M) | (18.9M) | (58.9M) | (1.8M) | (2.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (19.8M) | (19.8M) | (58.9M) | (2.0M) | (3.1M) |
| Per Share | |||||
| Basic EPS | ($313.61) | ($176.16) | ($3,712.24) | ($0.02) | ($26,974,080.43) |
| Diluted EPS | ($313.61) | ($176.16) | ($3,712.24) | ($0.02) | ($26,974,080.43) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 112371 | 112371 | 15873 | 85.0M | 0 |
| Diluted Shares Outstanding | 112371 | 112371 | 15873 | 85.0M | 0 |
| Profitability Metrics | |||||
| EBITDA | (18.4M) | (18.4M) | (58.3M) | (1.3M) | (2.3M) |
| D&A | 22.7K | 22.7K | 20.2K | 21.7K | 1.7K |
| EBIT | (18.4M) | (18.4M) | (58.4M) | (1.3M) | (2.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026